India Moves Forward in Healthcare Innovation as ICMR Shares New Biomedical Solutions
July 21: The Indian Council of Medical Research (ICMR) has taken a significant step towards strengthening healthcare innovation by transferring...
July 21: The Indian Council of Medical Research (ICMR) has taken a significant step towards strengthening healthcare innovation by transferring...
A new UCLA Health study examining more than 1.5 million emergency department (ED) visits found that female physicians request more...
New Delhi, July 17: The Delhi government has expanded its public healthcare infrastructure with the opening of 45 new Ayushman Jan...
Gandhinagar, July 17: Gujarat has strengthened its monsoon health preparedness by conducting a record 94 lakh malaria tests as part of...
July 15: India’s pharmaceutical sector is witnessing a strong rise in innovation activity, with India-origin pharma patents registering significant growth...
HCG Cancer Centre, Kolkata marked Doctors’ Day with an evening that celebrated not only doctors, but the spirit of teamwork that powers cancer care every day. The celebration...
Raichur, July 13: The District Administration of Raichur in collaboration with, GE HealthCare and United Way Bengaluru (UWBe), mark ten years of driving meaningful change...
Guwahati, July 10: The Assam government has presented a budget focused on employment generation, infrastructure development, healthcare improvement, and overall...
New Delhi, July 10: The government has announced that formulations containing high levels of alcohol will require appropriate licences and...
Milan, Italy, July 08 -- Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has today announced the publication of preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat methylmalonic acidemia (MMA), a severe inherited metabolic disorder. The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector encoding the MMUT gene led to sustained improvements in disease features in a validated mouse model of MMA, with effects lasting for the average lifespan of laboratory mice. Since the mice were treated when young, the study supports the durability of the gene therapy through postnatal growth and maturation of the liver. MMA is caused by a deficiency of methylmalonyl-CoA mutase, an enzyme that plays a critical role in the body’s metabolism of food. Its absence results in the accumulation of toxic metabolites that lead to recurrent metabolic crises, growth failure, neurological impairment, and multi-organ damage. In the study, researchers also treated mice with a dose containing an optimized MMUT transgene, thereby improving therapeutic efficacy. In the same mouse model of MMA, this...